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Abstract
Ouabain, an endogenous digitalis compound, has been detected in nanomolar concentrations in the plasma of several mam-
mals and is associated with the development of hypertension. In addition, plasma ouabain is increased in several hypertension 
models, and the acute or chronic administration of ouabain increases blood pressure in rodents. These results suggest a possible 
association between ouabain and the genesis or development and maintenance of arterial hypertension. One explanation for 
this association is that ouabain binds to the α-subunit of the Na+ pump, inhibiting its activity. Inhibition of this pump increases 
intracellular Na+, which reduces the activity of the sarcolemmal Na+/Ca2+ exchanger and thereby reduces Ca2+ extrusion. 
Consequently, intracellular Ca2+ increases and is taken up by the sarcoplasmic reticulum, which, upon activation, releases 
more calcium and increases the vascular smooth muscle tone. In fact, acute treatment with ouabain enhances the vascular 
reactivity to vasopressor agents, increases the release of norepinephrine from the perivascular adrenergic nerve endings and 
promotes increases in the activity of endothelial angiotensin-converting enzyme and the local synthesis of angiotensin II in the 
tail vascular bed. Additionally, the hypertension induced by ouabain has been associated with central mechanisms that increase 
sympathetic tone, subsequent to the activation of the cerebral renin-angiotensin system. Thus, the association with peripheral 
mechanisms and central mechanisms, mainly involving the renin-angiotensin system, may contribute to the acute effects of 
ouabain-induced elevation of arterial blood pressure. 
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Endogenous cardiac glycoside increases to nanomolar 
concentrations in the plasma of hypertensive humans and 
rats (1,2); in patients with diabetes (3), myocardial infarction 
(4), congestive heart failure (5) and other diseases, and after 
acute physical exercise (6). This substance was characterized 
as ouabain or as an isomer of ouabain (7) and is produced 
in the central nervous system (8,9), the adrenal cortex (10), 
and the heart (11). Acute administration of ouabain promotes 
a positive inotropic effect (12) and increases blood pressure 
and the contraction of vascular smooth muscle (13,14). These 
findings suggest that ouabain increases vascular resistance 
and induces hypertension (Figure 1). 
In addition to its hypertensive effects, endogenous oua-
bain also modifies cardiac function and modulates cellular 
proliferation and differentiation in the heart (15) and vascular 
smooth muscle (16). 
The primary site of ouabain action is generally assumed 
to be the α-subunit of Na+,K+-ATPase, which is a heterotrimer 
composed of α-, β- and γ-subunits which exist as isoforms 
(17,18). Ouabain inhibits Na+,K+-ATPase by binding mainly 
to the α2 and α3 isoforms of the α-subunit of the enzyme in 
rodents (13,19). This inhibition increases the Na+ concentration 
in the cytoplasm, which reduces the activity of the Na+/Ca2+ 
exchanger (NCX) and consequently increases the amount of 
Ca2+ available to activate contraction in tissues such as the 
heart, producing a positive inotropic effect (19,20). However, 
low concentrations of ouabain stimulate Ca2+ transients in 
arterial smooth muscle without raising cytosolic (Na+) (21). This 
apparent contradiction can be explained by the co-localization 
of the α2 and α3 isoforms of Na+,K+-ATPase and the NCX, 
which increases Na+ concentration only at the plasmerosome 
region in response to ouabain (19). The increase of Na+ con-
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centration in the plasmerosome region might reduce the activity 
of the NCX. As a result, intracellular calcium concentration 
increases, as do vascular tone and blood pressure (19,21). 
This suggests that ouabain acts as a pressor agent.
Xie and Cai (22) propose that low doses of ouabain, which 
are insufficient to inhibit Na+,K+-ATPase activity, could bind 
the caveolar Na+,K+-ATPase and activate some protein and 
lipid kinase cascades, thus generating several secondary 
messengers that, in turn, might modify cellular function. Thus, 
ouabain may modulate cellular proliferation and differentiation 
in the heart (15) and vascular smooth muscle (16), which could 
contribute to the maintenance of hypertension.
Ouabain might increase blood pressure via different 
mechanisms on different tissues and systems. In this review, 
we shall focus on the acute effects of ouabain on vascular 
reactivity and the central nervous system, mechanisms which 
might contribute to the development of hypertension. 
Acute effects of picomole quantities of 
ouabain on vascular reactivity
In normal human volunteers (23) and rats (14,24), short-
term iv administration of ouabain in the range of 10-30 nmol/
kg produces a pressor response that is peripheral in origin. 
In addition, an iv subpressor dose of ouabain, 0.1 mg/m2, 
enhances the ability of a single dose of norepinephrine to 
increase mean arterial pressure (25). Indeed, low doses of 
ouabain (6 and 18 µg/kg, which correspond to approximately 
10 and 30 nmol/kg) increase the vasoconstrictor response to 
phenylephrine (24).
In the reflex-blocked anesthetized rat, ouabain increases 
diastolic pressure by phentolamine-sensitive and -insensitive 
mechanisms (26,27). At the doses used, ouabain induced 
increases in diastolic pressure but did not alter the dose-
response curve for phenylephrine or the responsiveness to 
submaximal doses of norepinephrine. Because reflexes were 
blocked, the authors concluded that the short-term pressor 
effects of ouabain are not related to its direct central nervous 
system actions. Moreover, the authors suggested that the 
pressor actions of ouabain are mediated by norepinephrine 
released from sympathetic nerves as well as by a direct action 
on vascular smooth muscle cells. Presumably, both actions 
are due to the inhibition of Na+,K+-ATPase. Thus, the role of 
endogenous ouabain in hypertension would also include the 
amplification of contractile responses.
In some rat models of hypertension, including the SHR 
model (28), renovascular hypertension and L-NAME-
induced hypertension (29), acute ouabain administration 
Figure 1. A generalized scheme showing the central and peripheral actions of acute ouabain. RAS = renin-angiotensin system; Src = 
sarcoma kinase.
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increases blood pressure, whereas no change in blood 
pressure is observed in normotensive rats (14,30,31). These 
results suggest that the effects of ouabain are amplified in 
hypertensive conditions. We recently demonstrated in SHR 
that low picomole doses of ouabain (iv) increases systolic 
and diastolic blood pressure by a mechanism that seems 
to depend on activation of the renin-angiotensin system 
(31). However, because the effect of ouabain on diastolic 
blood pressure was not blocked by canrenone (1 mg/kg), 
we suggest that ouabain may have a mechanism of action 
that is independent of Na+ pump inhibition. 
Ouabain and a series of structurally related analogs 
have hypertensinogenic activity, regardless of their potency 
as Na+ pump inhibitors (32). In addition, Ward et al. (33) 
suggested that adrenocortical cells express ouabain recep-
tors that are distinct from the Na+ pumps. These findings 
could explain why the pressor effect of ouabain on diastolic 
blood pressure seems not to depend on its effect on the 
Na+ pump.
In the past few years, it has become apparent that bind-
ing of either endogenous or exogenous cardiotonic steroids, 
such as ouabain, to caveolar Na+,K+-ATPase evokes protein 
and lipid kinase cascades, thus generating several sec-
ondary messengers (22). This signaling pathway involves 
the association of protein tyrosine kinases (Src) with the 
Na+,K+-ATPase in a caveolar domain (34). Therefore, once 
the Na+,K+-ATPase/Src complex is activated by ouabain, 
Src is activated, initiating a cascade of signaling events. As 
a result, downstream effectors are activated, resulting in the 
activation of protein kinase cascades and the generation of 
second messengers. This leads to a cascade that involves 
the generation of reactive oxygen species (ROS), activa-
tion of extracellular signal-regulated protein kinase (ERK) 
through activation of its mitogen-activated protein kinase 
(MEK), activation of phosphatidylinositol 3-kinase (PI3K), 
stimulation of endocytosis and activation of Akt, as well as 
activation of protein kinase C (22,34,35). This binding of 
ouabain to Na+,K+-ATPase affects multiple cellular func-
tions, thereby influencing cell growth, heart hypertrophy 
and apoptosis (22). 
Ouabain can act directly on the vasculature to increase 
vascular resistance or to sensitize vascular beds to pressor 
responses produced by norepinephrine, angiotensin II, and 
phenylephrine (28,36-40). In vitro, picomole doses of oua-
bain enhance caffeine-induced contractures and increase 
the ability of phenylephrine to potentiate caffeine-induced 
contractions of rat isolated vascular preparations (41). 
These observations support the hypothesis that picomole 
quantities of ouabain should selectively interact with the 
high-affinity α2 and α3 isoforms of Na+,K+-ATPase to en-
hance the actions of vasoconstrictor agents.
Endothelium-derived factors might positively or nega-
tively modulate the vascular actions of ouabain. Thus, the 
endothelium modulates the actions of picomole quantities 
of acutely administered ouabain in vascular preparations 
from normotensive and hypertensive rats (28,29,40).
In the tail vascular bed from normotensive Wistar rats, 
Rossoni et al. (40) demonstrated that the acute perfusion 
of ouabain (10 nM) induces the release of a potassium 
channel opener and that the effects of ouabain are par-
tially modulated by the endothelium. On the other hand, 
in cultured rat aortic endothelial cells, ouabain (10 nM) 
contributes to the bradykinin-stimulated increase of nitric 
oxide (NO) production by inhibiting plasma membrane 
Na+,K+-ATPase activity and increasing intracellular Na+ 
concentration (42). Moreover, Eva et al. (43) demonstrated 
that small quantities of ouabain stimulate NO production 
in human umbilical artery endothelial cells via PI3K. The 
binding of ouabain to Na+,K+-ATPase initiates a signal via 
PI3K, which turns on the proliferation and survival pathways 
that involve Akt and that stimulate endogenous nitric oxide 
synthase (eNOS) and NO production (43). Because NO is 
an endothelial factor that activates Na+,K+-ATPase (44), 
we speculated that picomole quantities of ouabain could 
release NO, which, in turn, could stimulate Na+,K+-ATPase 
activity, reducing vascular reactivity in normotensive rats. 
In L-NAME-hypertensive rats, the acute administration of 
ouabain (10 nM) induces the release of endothelium-derived 
hyperpolarizing factor in the tail vascular bed (29). This 
and other results support the notion that the endothelium 
might modulate the action of acute and chronic ouabain 
administration (28,29,40,45). 
In the aorta from SHR, ouabain at micromolar con-
centrations releases an unknown vasoconstrictor factor 
not related to products from the arachidonic acid pathway 
or free radical release (39). However, the perfusion with 
a lower concentration of ouabain (1 nM) increases the 
sensitivity to phenylephrine in the tail vascular bed of SHR 
by a mechanism involving increased activity of endothelial 
angiotensin-converting enzyme and the local synthesis of 
angiotensin II (28). Indeed, the role of low-concentration 
ouabain (10 nM) in the local renin-angiotensin system was 
demonstrated in bovine adrenal glomerulosa cells (46). 
In that report, the authors showed that ouabain interacts 
with angiotensin II to stimulate aldosterone production in 
bovine adrenal glomerulosa cells. On the other hand, the 
central mechanism described above suggests that ouabain 
stimulates the brain renin-angiotensin system, leading to 
the production of angiotensin II, which further increases 
sympathetic tone and ultimately increases arterial blood 
pressure (47). We also found that the increases in systolic 
and diastolic blood pressure induced by low-dose ouabain 
(~0.3 nmol/kg) were blocked completely by pretreatment 
(iv) with 10 mg/kg losartan, although these increases 
were not affected by ganglionic blockade with 5 mg/kg 
hexamethonium, suggesting that ouabain, at least at this 
concentration, does not act on preganglionic neurons 
(28,31). On the other hand, the increase of blood pressure 
induced by 0.18 µg/kg ouabain in L-NAME-hypertensive rats 
is blocked by hexamethonium (29). Taken together, these 
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observations indicate that in SHR, ouabain activates the 
local renin-angiotensin system, which induces increases 
in vascular resistance and blood pressure. The classical 
effect of ouabain is the inhibition of Na+,K+-ATPase activity 
by binding mainly to the α2 and α3 isoforms of the α-subunit 
of the enzyme in rodents (13,19). Indeed, we demonstrated 
that in SHR, 1 nM ouabain activates rather than inhibits 
Na+,K+-ATPase activity in vascular smooth muscle (28), 
an observation similar to that described by Gao et al. (48) 
in cardiac myocytes. However, the angiotensin II released 
by the action of ouabain may also be able to stimulate 
Na+,K+-ATPase activity (49).
Although the peripheral actions of ouabain could contrib-
ute to increased blood pressure, the central mechanisms, 
already well established, are also important mediators of 
increased pressure induced by this digitalis. Therefore, the 
central mechanism of ouabain is described below.
Acute effects of ouabain on the central 
nervous system
The effects of ouabain on the central nervous system 
have been well established. Neurons express the α3 isoform 
of Na+/K+-ATPase, the most ouabain-sensitive isoform of 
the α-subunits, and therefore neurons are very sensitive 
to the effects of this substance.
Indeed, the acute administration of ouabain in some 
regions of the central nervous system, such as the me-
dian preoptic nucleus (50), paraventricular nucleus (51) or 
rostral ventrolateral medulla (52), causes dose-dependent 
increases in sympathetic nerve activity, blood pressure and 
heart rate. Therefore, these findings suggest that endog-
enous ouabain might be a regulator of sympathetic tone 
and arterial blood pressure by influencing some areas of 
cardiovascular pressor control. This hypothesis seems to 
be confirmed by reports that the sympathoexcitatory and 
pressor effects induced by ouabain can be reversed and 
prevented by the intracerebroventricular administration of 
antibody Fab fragments, which bind ouabain, blocking its 
actions (9,53). The sympathetic hyperactivity induced by 
ouabain and the consequent increase in blood pressure 
appear to involve the central renin-angiotensin system. 
This observation is supported by reports that the sympa-
thetic hyperactivity induced by ouabain is prevented by an 
AT1 receptor blocker (50-52), suggesting that the central 
renin-angiotensin system could be the sympathoexcitatory 
component involved in the hypertensinogenic effect of 
ouabain. In addition, the acute hypertensinogenic effect of 
ouabain is attenuated in transgenic rats that are deficient 
in brain angiotensinogen (54). Therefore, in some diseases 
that are accompanied by an increased level of endogenous 
ouabain, such as hypertension (1), heart failure (55) and 
diabetes (35), the increase in sympathoexcitatory activity 
could be due to the actions of ouabain on the central renin-
angiotensin system. In addition to the sympathoexcitatory 
activity induced by ouabain via the central renin-angiotensin-
aldosterone pathway, D’Amico at al. (56) demonstrated that 
the central endothelin system (periaqueductal gray area) 
of rats is also involved in this sympathetic activation and 
in the ouabain-induced hemodynamic effects. 
Ouabain release in the brain is very sensitive to sodium 
loading (9). This position is supported by the observation 
that the effects of sodium loading can be mimicked by intra-
hippocampal microinjection of ouabain (57). Indeed, acute 
intrahippocampal administration of an extremely low dose 
of ouabain (60 pg) in Dahl salt-sensitive rats (DSS) is as-
sociated with activation of the renin-angiotensin-aldosterone 
system in the hypothalamus and adrenal cortex, an increase 
in the adrenocortical level of marinobufagenin, inhibition of 
sodium pumps in the vasculature and kidney, and pressor 
and natriuretic responses (57). Moreover, the central admin-
istration of NaCl or NaCl loading in DSS or SHR rats induces 
increases in brain endogenous ouabain that, in turn, induce 
sympathoactivation and increase blood pressure (9,53). 
However, the evidence regarding the relationship between 
NaCl loading and increased ouabain level is contradictory. 
Manunta et al. (58) demonstrated in healthy humans that NaCl 
depletion produced an elevation in the plasma concentration 
of endogenous ouabain, but in the same study, 3 days of 
NaCl loading (171 mEq NaCl/day) caused a transient eleva-
tion in the plasma concentration of endogenous ouabain. 
In another report (59), acute NaCl loading in DSS and Dahl 
salt-resistant (DR) rats caused a transient increase in an 
ouabain-like compound in the pituitary gland, adrenal gland, 
and plasma, followed by a decrease to baseline. Therefore, 
it seems that the plasma level of endogenous ouabain may 
not be a good indicator of volume expansion because it 
displays transient response.
General considerations
Endogenous ouabain was discovered in humans 20 
years ago, and its effects on sodium pumps have been 
widely explored, although much remains to be clarified. In 
general, endogenous ouabain participates in the control of 
blood pressure and sodium balance (1), but it also modi-
fies cardiac function and modulates cellular proliferation 
and differentiation of the heart (15) and vascular smooth 
muscle (16). 
Acutely, ouabain in picomole quantities increases blood 
pressure (24,28-31), pressor and vascular reactivity to 
vasoconstrictor agents (14,24,28-31,40,41), and sympatho-
excitatory activity (9,53). These effects of ouabain are due 
at least in part to activation of the central and peripheral 
renin-angiotensin system (31,28,50-52).
Understanding the mechanisms of the effects of acute 
ouabain on the cardiovascular system is important because 
acute conditions of NaCl loading (13,57-59) or physical 
exercise (6) induce a sudden increase in the plasma 
level of endogenous ouabain. In some diseases, such as 
Hypertensive effect of ouabain 937
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hypertension (1,2), diabetes (3), myocardial infarction (4), 
and congestive heart failure (5), the basal plasma level 
of ouabain is increased. Therefore, acute conditions that 
elevate ouabain should be evaluated and studied to verify 
the systemic repercussions.
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